Janssen Biologics BV

Industry / private company


Location: Leiden

ISNI: 0000000406257026

ROR: https://ror.org/04cxegr21

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Regulatory Issues of Platform Trials: Learnings from EU-PEARL (2024) Nguyen QL, Hees K, Hernandez Penna S, König F, Posch M, Bofill Roig M, Meyer EL, et al. Journal article, Review article Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies (2023) Mcgonagle D, Mcinnes IBB, Deodhar A, Schett G, Shawi M, Chakravarty SDD, Kollmeier APP, et al. Journal article GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL (2022) Marzo-Ortega H, Theander E, Neuhold M, Bergmans P, Shawi M, Perate M, Contre C, et al. Conference contribution LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al. Journal article Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, et al. Journal article Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial (2021) Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, et al. Journal article Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease (2018) Koelink PJ, Wildenberg ME, Stitt LW, Feagan BG, Koldijk M, Van 'T Wout AB, Atreya R, et al. Journal article Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT) (2014) Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, et al. Journal article